Daniel S.W

Nov 21, 2024 | bmccancer.biomedcentral.com | Daniel S.W |Therapeutic Innovations |Aix Marseille |Faculté de Médecine

Department of Biomedical Sciences, Humanitas University, Milan, Italy Armando Santoro Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Via Manzoni 56, Rozzano, Milan, 20089, Italy Armando Santoro Department of Medical Oncology, Hospital Ramón Y Cajal, Madrid, Spain Garrido Pilar Department of Medical Oncology, National Cancer Center Singapore, Singapore, Singapore Daniel S.W. Tan Department of Medical Oncology, University Hospital, 12 de...

Oct 23, 2024 | bmccancer.biomedcentral.com | Daniel S.W |Therapeutic Innovations |Aix Marseille |Faculté de Médecine

On the data cut-off date (July 29, 2021), 112 of 156 patients completed screening and 111 patients were enrolled in the dose-confirmation and dose-expansion parts of the study. One patient was not treated due to physician’s decision. The primary reason for treatment discontinuation was disease progression (Supplementary Figure S2). Baseline demographics and disease characteristics are presented in Table 1. Overall, baseline characteristics across the treatment groups were well balanced.